Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQK-1001 in Sickle Cell Disease
NCT00842088Phase 2Completed
- Sponsor
- HemaQuest Pharmaceuticals, Inc.
- Start
- Mar 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of sodium 2,2-dimethylbutyrate in sickle cell disease (SCD) (2 arms), sponsored by HemaQuest Pharmaceuticals, Inc. Primary endpoint: Safety at 126 days. Started Mar 2009; status: completed.
02
Drugs
sodium 2,2-dimethylbutyrate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00842088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842088.